TRAX First Tracks Biotherapeutics, Inc.
Company Analysis
Latest News
First Tracks Biotherapeutics Announces Positive Phase 1b Data for Celiac Disease Drug ANB033
First Tracks Biotherapeutics announced positive top-line results from the first cohort of its Phase 1b clinical trial for ANB033, an investigational treatment...
🔴 First Tracks Biotherapeutics is trading 5% down today as biotech sector falls
First Tracks Biotherapeutics is trading at $32.25, down 5.29%, with no clear company-specific cause identified and the biotech sector also lower. - It closed...
🟢 First Tracks Biotherapeutics Surges on Positive Phase 1b Celiac Trial Results
First Tracks Biotherapeutics is trading at $37.35, up +20.64%, after announcing positive top-line results from Cohort 1 of its Phase 1b trial of ANB033 in...
TRAX Surges 21% on Eve of Celiac Trial Results — But Can a 30-Patient Study Justify a Billion-Dollar Bet?
Shares of First Tracks Biotherapeutics rocketed 20.9% to $38.50 in pre-market trading as investors positioned ahead of the company's most important milestone...
🟢 First Tracks Biotherapeutics is trading 21% up in pre-market ahead of October 12 ANB033 trial data
First Tracks Biotherapeutics is trading at $38.50, up 20.88%, ahead of its scheduled October 12 release of top-line ANB033 trial data. - The update is...
🟢 First Tracks Biotherapeutics is trading 7.1% up on October 8, 2026
First Tracks Biotherapeutics is trading at $32.75, up 7.06%, during the October 8 session, with no clear company-specific catalyst identified. - The...
🟢 First Tracks Biotherapeutics is trading 14.4% up in pre-market
First Tracks Biotherapeutics is trading 14.4% higher at $35.00 before the October 8, 2026 open; the cause is unclear. - Its investor-relations release page...
🟢 First Tracks Biotherapeutics is trading 8% up in pre-market with no clear catalyst identified
First Tracks Biotherapeutics is trading at $34.00, up 8.31% in pre-market, with no company-specific cause identified. - Shares closed at $31.39 on October...
🔴 First Tracks Biotherapeutics is trading 5% down today amid broad biotech weakness
First Tracks Biotherapeutics is trading at $31.34 (-5.01%) as biotech-sector weakness coincides with the decline; no clear company-specific announcement...
🔴 First Tracks Biotherapeutics is trading 5.8% down; catalyst remains unclear
First Tracks Biotherapeutics is trading at $31.34, down 5.84%, with no clear catalyst identified. - It was down 1.89% at the October 2 close; no new company...
🟢 First Tracks Biotherapeutics is trading 5% up today
First Tracks Biotherapeutics is trading at $36.23, up 5.24%, with no confirmed company-specific announcement or catalyst dated September 28, 2026. - A...
🔴 First Tracks Biotherapeutics is trading 5.19% down today with no confirmed direct catalyst
First Tracks Biotherapeutics is trading at $33.97, down 5.19%, with no confirmed direct catalyst identified for September 25, 2026. - Recent...
🔴 First Tracks Biotherapeutics is trading 5.32% down today as rising yields and oil pressure growth stocks
First Tracks Biotherapeutics is trading 5.32% lower at $34.71, with the decline appearing mainly tied to broader risk-off trading rather than a fresh...
🔴 First Tracks Biotherapeutics is trading 10.77% down today as broad market losses pressured growth assets
First Tracks Biotherapeutics is trading 10.77% lower at $36.61 as a broad September 23, 2026 market sell-off weighed on growth-oriented assets. - The Nasdaq...
🔴 First Tracks Biotherapeutics is trading 5.4% down today amid broader market weakness
First Tracks Biotherapeutics is trading 5.4% lower at $38.80 amid broader market weakness. - On September 23, 2026, the Nasdaq Composite was down 1.05%;...
🟢 First Tracks Biotherapeutics is trading 5.5% up today amid broader biotech momentum
First Tracks Biotherapeutics is trading 5.5% up now at $41.14, with broader biotech-sector momentum the clearest explanation. - Shares rose from the September...
First Tracks Biotherapeutics earns outperform rating at Evercore, targeting immunology breakthroughs
Evercore ISI initiated coverage of First Tracks Biotherapeutics Inc. with an outperform rating. The firm established a price target of $65.00 per share for...
🟢 First Tracks Biotherapeutics is trading 6.9% up today after Guggenheim initiated coverage with a Buy rating
First Tracks Biotherapeutics is trading 6.9% up at $41.17 after Guggenheim initiated coverage with a Buy rating and a $100 price target on September 16,...
🟢 First Tracks Biotherapeutics is trading 5% up today after Guggenheim's Buy rating and $100 target
First Tracks Biotherapeutics is trading at $40.40, up +5.02%, after Guggenheim initiated coverage on September 16, 2026, with a Buy rating and a $100 price...
🟢 First Tracks Biotherapeutics is trading 5% up today; no clear catalyst identified
First Tracks Biotherapeutics is trading 5.08% up at $38.29, reversing part of its recent decline, with no clear company-specific catalyst identified. - No...